An effective vaccine against Toxoplasma gondii is an ideal strategy for controlling acute or chronic toxoplasmosis. In order to boost immune reactions to various antigens, liposomes may be utilized as immunoadjuvants. We encapsulated soluble Toxoplasma antigen (SA) and imiquimod adjuvant in 1, 2-Dioleoyl-3-trimethylammonium Propane (DOTAP) liposomes to evaluate the immune response induced by this vaccine. Three times with 2-week intervals, BALB/C mice were immunized subcutaneously with different formulations. The type of generated immune reaction, as well as the protection extent, was assessed through the percent survival survey of BALB/c mice after challenge with Toxoplasma gondii, the evaluation immune reaction with the generation of cytokine (IFN-γ, IL-4), and titration of IgG isotypes. Less mortality was observed in the immunized mice by liposome DOTAP + imiquimod + SA that was meaningfully different (P<0.01) in comparison to other groups. The IgG2a and IFN-γ secretion highest levels were seen with liposome DOTAP + imiquimod + SA more than the control group (P<0.001) and (P<0.0001), respectively. The results of this research reveal that a cellular immune reaction is produced by the formulation of liposome DOTAP + imiquimod + SA, which is protective facing T. gondii challenge